Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

Danish biopharma giant Novo Nordisk (NOV: N) is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...